New hope for KRAS G12D lung cancer: targeted drug combo enters trial
NCT ID NCT07554859
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new drug called GFH375, alone or combined with other drugs (cetuximab or pemetrexed), as a first treatment for advanced non-small cell lung cancer with a specific KRAS G12D mutation. The study will enroll 90 people who have not had prior treatment. The goal is to see if these treatments shrink tumors and are safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GFH375 (a targeted drug), cetuximab, and pemetrexed
What this could lead to
If successful, this could provide a new first-line treatment option for people with a specific type of advanced lung cancer (KRAS G12D mutation).
What could go wrong
This is an early Phase 2 trial with only 90 participants, so results may not apply broadly. The drug may not work better than existing treatments or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact